Intra-Tumor Heterogeneity Revealed by Mass Spectrometry Imaging Is Associated with the Prognosis of Breast Cancer.
HER2-positive breast cancer
intra-tumor heterogeneity
long-term outcome
mass spectrometry imaging
prognosis
tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Aug 2021
27 Aug 2021
Historique:
received:
29
06
2021
revised:
23
08
2021
accepted:
24
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
Intra-tumor heterogeneity (ITH) results from the coexistence of genetically distinct cancer cell (sub)populations, their phenotypic plasticity, and the presence of heterotypic components of the tumor microenvironment (TME). Here we addressed the potential association between phenotypic ITH revealed by mass spectrometry imaging (MSI) and the prognosis of breast cancer. Tissue specimens resected from 59 patients treated radically due to the locally advanced HER2-positive invasive ductal carcinoma were included in the study. After the on-tissue trypsin digestion of cellular proteins, peptide maps of all cancer regions (about 380,000 spectra in total) were segmented by an unsupervised approach to reveal their intrinsic heterogeneity. A high degree of similarity between spectra was observed, which indicated the relative homogeneity of cancer regions. However, when the number and diversity of the detected clusters of spectra were analyzed, differences between patient groups were observed. It is noteworthy that a higher degree of heterogeneity was found in tumors from patients who remained disease-free during a 5-year follow-up (
Identifiants
pubmed: 34503159
pii: cancers13174349
doi: 10.3390/cancers13174349
pmc: PMC8431441
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Narodowe Centrum Nauki
ID : 2016/23/B/NZ4/03901
Références
J Proteome Res. 2010 Apr 5;9(4):1854-63
pubmed: 20170166
Mol Cell Endocrinol. 2018 Sep 5;472:68-79
pubmed: 29183805
Science. 2018 Jul 27;361(6400):
pubmed: 29930089
Nat Med. 2016 Jan;22(1):105-13
pubmed: 26618723
Nat Rev Cancer. 2010 Sep;10(9):639-46
pubmed: 20720571
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
J Pathol. 2015 Jan;235(1):3-13
pubmed: 25201776
Int J Mol Sci. 2020 Aug 31;21(17):
pubmed: 32878024
Cancers (Basel). 2021 Jul 05;13(13):
pubmed: 34282768
Front Oncol. 2021 Mar 11;11:610303
pubmed: 33777750
Histol Histopathol. 2019 Jan;34(1):13-24
pubmed: 29978449
Breast Cancer Res Treat. 2019 Jan;173(1):55-64
pubmed: 30302588
Pathobiology. 2015 Sep;82(3-4):142-52
pubmed: 26330355
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Target Oncol. 2016 Oct;11(5):579-591
pubmed: 27181019
J Proteome Res. 2013 Apr 5;12(4):1847-55
pubmed: 23480610
Oncotarget. 2016 Mar 1;7(9):10051-63
pubmed: 26840267
Biochim Biophys Acta. 2010 Jan;1805(1):105-17
pubmed: 19931353
Nat Methods. 2021 Jan;18(1):1
pubmed: 33408396
Nucleic Acids Res. 2017 Jan 4;45(D1):D1100-D1106
pubmed: 27924013
Breast Dis. 2010;32(1-2):25-33
pubmed: 21778580
J Cancer Res Clin Oncol. 2013 Jan;139(1):85-95
pubmed: 22955295
Carcinogenesis. 2017 Sep 1;38(9):900-909
pubmed: 28911002
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
Endocr Pathol. 2019 Dec;30(4):250-261
pubmed: 31664609
Clin Adv Hematol Oncol. 2016 Jul;14(7):520-30
pubmed: 27379947
Nat Methods. 2014 Apr;11(4):417-22
pubmed: 24584193
Proteomics. 2016 Jun;16(11-12):1613-21
pubmed: 27168173
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Adv Cancer Res. 2017;134:201-230
pubmed: 28110651
Breast Cancer. 2017 Jan;24(1):3-15
pubmed: 27138387
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12244-12249
pubmed: 27791011
Proteomics Clin Appl. 2018 Jan;12(1):
pubmed: 28801933
Breast Cancer Res Treat. 2020 Jun;181(3):519-527
pubmed: 32335801
Breast Cancer Res Treat. 2019 Nov;178(2):283-294
pubmed: 31402409
Breast Cancer Res. 2011;13(6):227
pubmed: 22078026
Nat Methods. 2007 Oct;4(10):828-33
pubmed: 17901873
Genome Biol. 2015 May 22;16:107
pubmed: 25994018
Breast. 2014 Jun;23(3):259-63
pubmed: 24613255
Science. 1976 Oct 1;194(4260):23-8
pubmed: 959840
J Proteome Res. 2008 Jan;7(1):113-22
pubmed: 18067247
J Pathol. 2010 Apr;220(5):562-73
pubmed: 20099298
Breast Cancer Res Treat. 2015 Feb;149(3):727-41
pubmed: 25667103
Nature. 2012 Jun 28;486(7404):532-6
pubmed: 22722830
Breast Cancer Res. 2019 Dec 19;21(1):147
pubmed: 31856876
Nat Med. 2015 Jul;21(7):751-9
pubmed: 26099045
Nature. 2014 Aug 14;512(7513):155-60
pubmed: 25079324
Cell. 2018 Sep 6;174(6):1373-1387.e19
pubmed: 30193111
Anal Chem. 2015 Apr 21;87(8):4110-6
pubmed: 25837572
Nature. 2012 Apr 04;486(7403):395-9
pubmed: 22495314
Cancer Cell. 2010 Jan 19;17(1):77-88
pubmed: 20129249
Nat Rev Cancer. 2012 Apr 19;12(5):323-34
pubmed: 22513401
Cell. 2012 May 25;149(5):994-1007
pubmed: 22608083
J Mol Histol. 2019 Feb;50(1):1-10
pubmed: 30390197
PLoS One. 2015 Jul 31;10(7):e0134256
pubmed: 26230717
Mass Spectrom Rev. 2007 Jul-Aug;26(4):606-43
pubmed: 17471576
Nat Rev Genet. 2015 Jan;16(1):57-66
pubmed: 25446315
Nature. 2012 Jan 18;481(7381):306-13
pubmed: 22258609
Science. 2014 Jan 10;343(6167):189-193
pubmed: 24336570
Nature. 2012 Jan 11;481(7382):506-10
pubmed: 22237025
Breast Cancer Res. 2007;9(1):R6
pubmed: 17239243
Life Sci. 2019 Dec 15;239:117009
pubmed: 31669239